Study indicates potential breakthrough HIV drug
Pharmaphorum Media Limited | July 05, 2018
French biotech Abivax’s might be on the verge of HIV cure and prevention discovery, after achieving a significant reduction of viral load patients during the first 28 days of treatment. The company has announced results from the first group of patients in its most recent phase 2a trial testing the potential HIV cure treatment codenamed ABX464. The study aimed at accessing the effects of Abivax treatment on HIV DNA in blood and in rectal tissue in HIV patients and was conducted at the Germans Trias I Pujol University Hospital Badalona in Barcelona.